Corline Biomedical: Brief Comment on EU Patent

Research Note

2020-07-08

16:23

Redeye has a positive view on the European Patent Office (UPO) intension to approve Corline’s patent application involving the treatment and protection of blood vessels prior to transplantation. Together with the orphan drug designation (ODD), we argue Corline’s heparin technology is well-protected in the European market, importantly mitigating the IP risk. Corline holds the same patent in US and China.

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.